Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial.

Leiter, Lawrence A et al.·Cardiovascular diabetology·2019·
RPEP-043162019RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Key Numbers

How They Did This

Why This Research Matters

What This Study Doesn't Tell Us

Trust & Context

Original Title:
Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial.
Published In:
Cardiovascular diabetology, 18(1), 73 (2019)
Database ID:
RPEP-04316

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-04316·https://rethinkpeptides.com/research/RPEP-04316

APA

Leiter, Lawrence A; Bain, Stephen C; Hramiak, Irene; Jódar, Esteban; Madsbad, Sten; Gondolf, Theis; Hansen, Thomas; Holst, Ingrid; Lingvay, Ildiko. (2019). Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial.. Cardiovascular diabetology, 18(1), 73. https://doi.org/10.1186/s12933-019-0871-8

MLA

Leiter, Lawrence A, et al. "Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial.." Cardiovascular diabetology, 2019. https://doi.org/10.1186/s12933-019-0871-8

RethinkPeptides

RethinkPeptides Research Database. "Cardiovascular risk reduction with once-weekly semaglutide i..." RPEP-04316. Retrieved from https://rethinkpeptides.com/research/leiter-2019-cardiovascular-risk-reduction-with

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.